Stephen J Ullrich

US Patent:

6495520, Dec 17, 2002

Filed:

Feb 19, 1999

Appl. No.:

09/252656

Inventors:

Reinhard Ebner - Gaithersburg MD
Guo-Liang Yu - Berkeley CA
Steven M. Ruben - Olney MD
Jun Zhang - Bethesda MD
Stephen Ullrich - Rockville MD
Yifan Zhai - Gaithersburg MD

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

A61K 3818

US Classification:

514 12, 530300, 530324, 530350

Abstract:

The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

US Patent:

6635743, Oct 21, 2003

Filed:

Mar 10, 2000

Appl. No.:

09/523323

Inventors:

Reinhard Ebner - Gaithersburg MD
Guo-Liang Yu - Berkeley CA
Steven M. Ruben - Olney MD
Stephen Ullrich - Rockville MD
Yifan Zhai - Guilford CT

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

C07K 1600

US Classification:

53038823, 5303873, 5303881, 5303891, 5303892, 5303871, 435 71, 930144

Abstract:

The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

US Patent:

7964190, Jun 21, 2011

Filed:

Feb 28, 2003

Appl. No.:

10/375680

Inventors:

Reinhard Ebner - Gaithersburg MD, US
Guo-Liang Yu - Berkeley CA, US
Steven M Ruben - Brookeville MD, US
Yifan Zhai - Rockville MD, US
Stephen Ullrich - Rockville MD, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

A61K 38/21
A61K 39/00
A61K 39/395
A61K 45/00
C07K 14/00

US Classification:

4241301, 424 851, 424 854, 4241391, 530351, 5303871

Abstract:

The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

US Patent:

20020055147, May 9, 2002

Filed:

Jul 20, 2001

Appl. No.:

09/908599

Inventors:

Haodong Li - Gaithersburg MD, US
George Seibel - Saint Davis PA, US
Stephen Ullrich - Rockville MD, US
Francis Luscinskas - Milton MA, US

International Classification:

C12P021/02
C07H021/04
C12N005/06
C07K014/52

US Classification:

435/069500, 435/325000, 530/351000, 536/023500

Abstract:

The present invention relates to a novel CK-13 protein which is a member of the chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK-13 protein. CK-13 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CKCK-13 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

US Patent:

20020064869, May 30, 2002

Filed:

Feb 20, 1998

Appl. No.:

09/027287

Inventors:

REINHARD EBNER - GAITHERSBURG MD, US
GUO-LIANG YU - DARNESTOWN MD, US
STEVEN M. RUBEN - OLNEY MD, US
STEPHEN ULLRICH - ROCKVILLE MD, US

Assignee:

Human Genome Sciences, Inc.

International Classification:

C12N015/63
C07H021/04
C12N015/00
C12N015/74
C12N005/06
C12N015/70
C12N015/09

US Classification:

435/320100, 435/069100, 435/325000, 536/023500

Abstract:

The present invention relates to a novel member of the TNF-Ligand superfamily, Apoptosis Inducing Molecule II (AIM II). In particular, isolated nucleic acid molecules are provided encoding the human AIM II protein. AIM II polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, autoimmune disease, graft versus host disease, and to inhibit neoplasia, such as tumor cell growth.

US Patent:

20020115112, Aug 22, 2002

Filed:

Aug 15, 2001

Appl. No.:

09/929493

Inventors:

Guo-Liang Yu - Berkeley CA, US
Reinhard Ebner - Gaithersburg MD, US
Jian Ni - Germantown MD, US
Craig Rosen - Laytonsville MD, US
Stephen Ullrich - Rockville MD, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

C07K016/24
G01N033/567
G01N033/53
A61K039/395

US Classification:

435/007200, 530/388230, 424/145100

Abstract:

The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

US Patent:

20020187526, Dec 12, 2002

Filed:

Mar 1, 2002

Appl. No.:

10/084971

Inventors:

Steven Ruben - Olney MD, US
Stephen Ullrich - Rockville MD, US
Kevin Baker - Darnestown MD, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

C12P021/02
C07H021/04
C07K014/52
C12N005/06

US Classification:

435/069500, 435/320100, 435/325000, 536/023500, 530/351000

Abstract:

The present invention relates to Neutrokine-alpha binding polypeptides (NAR). In particular, isolated nucleic acid molecules are provided encoding human NAR protein. NAR polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of NAR activity.

US Patent:

20030143696, Jul 31, 2003

Filed:

Nov 1, 2002

Appl. No.:

10/285572

Inventors:

Haodong Li - Gaithersburg MD, US
George Seibel - Saint Davids PA, US
Stephen Ullrich - Rockville MD, US
Francis Luscinskas - Milton MA, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

C07K014/52
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/069500, 435/320100, 435/325000, 530/351000, 536/023500

Abstract:

The present invention relates to a novel CK-13 protein which is a member of the chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK-13 protein. CK-13 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CK-13 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.